Virax Biolabs Group Stock Probability of Future Stock Price Finishing Over 1.97
| VRAX Stock | USD 1.70 0.11 6.08% |
Virax |
Virax Biolabs Target Price Odds to finish over 1.97
The tendency of Virax Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 1.97 or more in 90 days |
| 1.70 | 90 days | 1.97 | about 57.93 |
Based on a normal probability distribution, the odds of Virax Biolabs to move over $ 1.97 or more in 90 days from now is about 57.93 (This Virax Biolabs Group probability density function shows the probability of Virax Stock to fall within a particular range of prices over 90 days) . Probability of Virax Biolabs Group price to stay between its current price of $ 1.70 and $ 1.97 at the end of the 90-day period is about 25.5 .
Given the investment horizon of 90 days Virax Biolabs Group has a beta of -0.83. This entails as returns on the benchmark increase, returns on holding Virax Biolabs are expected to decrease at a much lower rate. During a bear market, however, Virax Biolabs Group is likely to outperform the market. Additionally Virax Biolabs Group has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Virax Biolabs Price Density |
| Price |
Predictive Modules for Virax Biolabs
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Virax Biolabs Group. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Virax Biolabs Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Virax Biolabs is not an exception. The market had few large corrections towards the Virax Biolabs' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Virax Biolabs Group, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Virax Biolabs within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.43 | |
β | Beta against Dow Jones | -0.83 | |
σ | Overall volatility | 0.35 | |
Ir | Information ratio | -0.07 |
Virax Biolabs Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Virax Biolabs for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Virax Biolabs Group can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Virax Biolabs Group generated a negative expected return over the last 90 days | |
| Virax Biolabs Group has high historical volatility and very poor performance | |
| Virax Biolabs Group may become a speculative penny stock | |
| Virax Biolabs Group currently holds 224.3 K in liabilities. Virax Biolabs Group has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Virax Biolabs' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 156.42 K. Net Loss for the year was (6.74 M) with loss before overhead, payroll, taxes, and interest of (1.36 K). | |
| Virax Biolabs Group currently holds about 21.76 K in cash with (6.25 M) of positive cash flow from operations. | |
| Latest headline from finance.yahoo.com: Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland |
Virax Biolabs Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Virax Stock often depends not only on the future outlook of the current and potential Virax Biolabs' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Virax Biolabs' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2 M | |
| Cash And Short Term Investments | 3.6 M |
Virax Biolabs Technical Analysis
Virax Biolabs' future price can be derived by breaking down and analyzing its technical indicators over time. Virax Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Virax Biolabs Group. In general, you should focus on analyzing Virax Stock price patterns and their correlations with different microeconomic environments and drivers.
Virax Biolabs Predictive Forecast Models
Virax Biolabs' time-series forecasting models is one of many Virax Biolabs' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Virax Biolabs' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Virax Biolabs Group
Checking the ongoing alerts about Virax Biolabs for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Virax Biolabs Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Virax Biolabs Group generated a negative expected return over the last 90 days | |
| Virax Biolabs Group has high historical volatility and very poor performance | |
| Virax Biolabs Group may become a speculative penny stock | |
| Virax Biolabs Group currently holds 224.3 K in liabilities. Virax Biolabs Group has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Virax Biolabs' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 156.42 K. Net Loss for the year was (6.74 M) with loss before overhead, payroll, taxes, and interest of (1.36 K). | |
| Virax Biolabs Group currently holds about 21.76 K in cash with (6.25 M) of positive cash flow from operations. | |
| Latest headline from finance.yahoo.com: Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland |
Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.